Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

DiaMedica Therapeutics, Inc. (DMAC) vs ARS Pharmaceuticals, Inc. (SPRY)

DiaMedica Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($422.2M and $412.7M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −184.3%) and the higher return on invested capital (0.00% vs −335.7%). Across the 14 metrics below, DiaMedica Therapeutics, Inc. leads on 11 and ARS Pharmaceuticals, Inc. on 3.

Valuation

Metric DMAC SPRY Biotechnology median
P/E n/m n/m 7.88
P/S n/m 3.47 11.47
P/B 11.16 32.38 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 3.70 10.73
Earnings yield (9.07%) (53.43%) (28.84%)
Free cash flow yield (7.37%) (52.35%) (23.03%)

Profitability

Metric DMAC SPRY Biotechnology median
Gross margin 0.00% 71.37% 65.16%
Operating margin 0.00% (184.96%) 0.00%
Net margin 0.00% (184.26%) 0.00%
Free cash flow margin 0.00% (167.97%) 0.00%
Return on equity (114.62%) (210.37%) (57.72%)
Return on assets (98.18%) (76.54%) (49.22%)
Return on invested capital 0.00% (335.65%) 0.00%

Growth

Metric DMAC SPRY Biotechnology median
Revenue growth (TTM) — 4.08% 5.64%
EPS growth (last fiscal year) (16.67%) (2,275.00%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC SPRY Biotechnology median
Debt to equity 0.00 13.72 0.00
Current ratio 6.72 3.48 4.73
Net debt to EBITDA 1.70 0.42 0.96

Dividend

Metric DMAC SPRY Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DMAC SPRY Biotechnology median
Market cap 422.24m 412.71m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack